CoLAB AccelBio

AccelBio is a collaborative laboratory that aims to be the bridge that brings biomedical science closer to the market. With a set of partners that cover all the necessary capacities and expertise to drive drug discovery, AccelBio selects fundamental research discoveries and cutting-edge technology platforms and tools and guides the transformation of breakthrough science into validated and investment-worthy assets. AccelBio bridges academic research groups and start-ups with industry-standard drug discovery capabilities - target validation, assay development, high-throughput screening, in silico modelling, medicinal chemistry, in vitro and in vivo testing, IP support and business development. Innovative platforms are also being developed...

Health,research,development and innovation,drug discovery,biotechnology,translational research,drug development,pharmaceutical,oncology,neuroscience,immunology,life sciences,multiomics,target discovery and validation,in vitro models,technology transfer,business development,preclinical studies,organoids,high throughput screening,drug design,biotech,and antibody drug conjugates

Colab accelbio operates in the Biotechnology research industry.

Colab accelbio's revenue is 11m - 100m

Colab accelbio has 11 - 50 employees.